Cullinan Therapeutics Licenses Rights to Velinotamig

ReutersJun 4, 2025 8:11 PM

June 4 (Reuters) - Cullinan Therapeutics Inc CGEM.O:

CULLINAN THERAPEUTICS LICENSES RIGHTS TO VELINOTAMIG, A CLINICAL-STAGE BCMA-DIRECTED BISPECIFIC T CELL ENGAGER, FROM GENRIX BIO FOR DEVELOPMENT IN AUTOIMMUNE DISEASES
CULLINAN THERAPEUTICS INC - TO PAY $20 MILLION UPFRONT LICENSE FEE TO GENRIX BIO
CULLINAN THERAPEUTICS INC - GENRIX ELIGIBLE FOR UP TO $292 MILLION IN MILESTONES
CULLINAN THERAPEUTICS INC - EXPECTS CASH RESOURCES TO LAST INTO 2028
CULLINAN THERAPEUTICS : GENRIX TO RECEIVE UP TO AN ADDITIONAL $400M IN SALES-BASED MILESTONES

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Recommended Articles

AST SpaceMobile Shares Plunge in Overnight Trading, What Happened? Will It Affect SpaceX?

TradingKey - In the early hours of April 19, AST SpaceMobile’s (ASTS.US) seventh broadband communication satellite, BlueBird 7, launched from Cape Canaveral aboard Blue Origin’s New Glenn rocket. While the rocket’s first stage was successfully recovered, the second stage deployed the satellite into

Is Netflix Still Worth Buying After a 10% Stock Slump? Who Is the Better Investment Compared to Disney?

TradingKey - After the market close on April 16, streaming giant Netflix delivered a seemingly impressive Q1 earnings report: revenue grew 16% year-over-year to $12.25 billion, exceeding the market expectation of $12.17 billion; earnings per share (EPS) reached $1.23, nearly doubling from $0.66 in t

Allbirds Ditches Sneakers and Pivots to AI Computing - Is BIRD Stock Still Worth Buying After a 600% Surge?

TradingKey - Allbirds surged 600% after announcing a full pivot to GPU leasing as NewBird AI. Shares pulled back 30% the next day. Key support $10, targets $13.30 and $15.90.

Nvidia Launches Ising Model Driving Quantum Sector Surge, QUBT vs IONQ, Which Is More Worth Investing In?

TradingKey - Following Nvidia’s launch of the Ising model, the quantum computing sector was rapidly galvanized; however, a company’s own commercialization progress remains the true determinant of its investment value. In comparison, IonQ’s revenue growth and execution capabilities are clearer, while QUBT is in an earlier stage, offering greater potential upside along with higher risk.

Why the Dollar’s Continuous Depreciation Still Fails to Save the Yen? When Will the Yen Strengthen?

TradingKey - As the U.S. Dollar Index continues to pull back from its highs amid easing geopolitical tensions and weakened rate cut expectations, the Japanese yen, instead of strengthening, has persistently hovered around the key psychological level of 160, repeatedly nearing the Japanese authoritie

Featured Tools